Skip to main content

The FDA can single-handedly reduce drug price-gouging. Why is it waiting? – LA Times

By January 7, 2016News
johns-hopkins-logo

johns-hopkins-logo

The crisis in soaring drug prices has produced not merely a new class of public enemies to skewer — step forward, Martin Shkreli! — but the best evidence yet that the nation’s healthcare regulatory priorities are out of whack.

{iframe}http://www.latimes.com/business/hiltzik/la-fi-mh-the-fda-can-single-handedly-stop-20160105-column.html{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.